Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XPF-005 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| XPF-005 | ACTIVE_COMPARATOR | Active treatment: XPF-005 Gel |
| Vehicle gel | PLACEBO_COMPARATOR | Placebo: XPF-005 Vehicle Gel |
| Name | Type | Description |
|---|---|---|
| XPF-005 | DRUG | Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris. |
| Placebo | DRUG | - |
Key Inclusion Criteria: 1. Aged between 18 and 50, inclusive 2. Male or female, agree to comply with contraceptive requirements 3. Signed Informed Consent Form 4. Clinical diagnosis of facial acne vulgaris defined as: * 25 to 75 inflammatory lesions, * 20 to 120 non-inflammatory lesions, and...
XPF-005 is an investigational small molecule being developed for the treatment of acne vulgaris. It is administered as a topical gel. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
The molecular target of XPF-005 has not been disclosed. As a small molecule, it is designed to interact with specific biological pathways involved in acne vulgaris, but the exact target is not publicly available at this time.
XPF-005 is being developed by Xenon Pharmaceuticals Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XENE. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
XPF-005 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a safety, tolerability, efficacy, and exposure study of the topical gel. The drug remains investigational and has not received FDA approval.
XPF-005 has been studied in one completed Phase 1 clinical trial with the identifier NCT02656043. This trial, titled 'A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel,' enrolled 213 participants with acne vulgaris in Canada. The study was randomized, double-blind, and placebo-controlled.
Yes, XPF-005 is also known as XEN801. The clinical trial NCT02656043 refers to the drug as XEN801, indicating that XPF-005 and XEN801 are alternative names for the same investigational compound.